Wave Life Sciences (NASDAQ:WVE) Shareholders Are up 12% This Past Week, but Still in the Red Over the Last Five Years
Wave Life Sciences (NASDAQ:WVE) Shareholders Are up 12% This Past Week, but Still in the Red Over the Last Five Years
This month, we saw the Wave Life Sciences Ltd. (NASDAQ:WVE) up an impressive 49%. But don't envy holders -- looking back over 5 years the returns have been really bad. In fact, the share price has declined rather badly, down some 66% in that time. Some might say the recent bounce is to be expected after such a bad drop. We'd err towards caution given the long term under-performance.
本月,我们看到了Wave Life Sciences Ltd.(纳斯达克:WVE)惊人的上涨了49%。但不要羡慕股东-回顾过去5年的回报真的很糟糕。实际上,股价在那段时间内下跌了相当严重,下降了约66%。有人可能会说,这一最新反弹是可以预期的,因为经历了如此糟糕的跌幅。考虑到长期表现低迷,我们倾向于谨慎。
The recent uptick of 12% could be a positive sign of things to come, so let's take a look at historical fundamentals.
纳斯达克股票代码:SCWX的收益和营收增长于本文发布于2024年7月4日。SecureWorks的股东在今年获得了10%的总回报。不幸的是,这低于市场回报。但好消息是依旧有所收益,并且肯定比过去五年每年约8%的亏损要好。因此,这可能表明企业已经扭转了其命运。我发现长期股价作为业务绩效的代理非常有趣。但是,要真正获得洞察力,我们还需要考虑其他信息。尽管如此,请注意,SecureWorks在我们的投资分析中显示了2个警告信号,您需要知道……
Given that Wave Life Sciences didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
鉴于Wave Life Sciences在过去12个月内没有盈利,我们将重点关注营业收入增长,以形成其业务发展的快速视图。一般来说,没有盈利的公司预计每年增长收入,并且增长速度不错。这是因为如果收入增长微不足道,而且从未盈利,很难确信公司将可持续。
Over five years, Wave Life Sciences grew its revenue at 40% per year. That's better than most loss-making companies. Unfortunately for shareholders the share price has dropped 11% per year - disappointing considering the growth. It's safe to say investor expectations are more grounded now. Given the revenue growth we'd consider the stock to be quite an interesting prospect if the company has a clear path to profitability.
在过去的五年中,Wave Life Sciences的营业收入增长率为每年40%。这比大多数亏损的公司都要好。不幸的是,股东的股票价格每年下降11%-考虑到增长,这令人失望。可以说,投资者的期望现在更为现实。鉴于营业收入的增长,如果公司有明确的盈利路径,我们认为该股票是一个相当有趣的前景。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
以下图像显示了公司的营业收入和盈利(随时间变化)(单击以查看准确的数字)。
If you are thinking of buying or selling Wave Life Sciences stock, you should check out this FREE detailed report on its balance sheet.
如果您正在考虑购买或出售Wave Life Sciences公司的股票,您应该查看其资产负债表的此免费详细报告。
A Different Perspective
不同的观点
It's good to see that Wave Life Sciences has rewarded shareholders with a total shareholder return of 60% in the last twelve months. There's no doubt those recent returns are much better than the TSR loss of 11% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for Wave Life Sciences that you should be aware of.
很高兴看到Wave Life Sciences在过去12个月中以总股东回报率60%回报股东。毫无疑问,最近的回报要比过去五年每年的TSR亏损11%要好得多。长期损失使我们谨慎,但短期的TSR收益肯定暗示着更光明的未来。
We will like Wave Life Sciences better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
如果我们看到一些大型内部人员购买,则更喜欢Wave Life Sciences。在等待时,请查看此带有相当多最近内部购买的被低估股票(主要是小盘股)的免费列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。